Presentation is loading. Please wait.

Presentation is loading. Please wait.

Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study  Ryutaro Kakinuma, MD, PhD, Masayuki Noguchi, MD, PhD, Kazuto Ashizawa,

Published bySusanna Toivonen Modified over 5 years ago

Similar presentations

Presentation on theme: "Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study  Ryutaro Kakinuma, MD, PhD, Masayuki Noguchi, MD, PhD, Kazuto Ashizawa,"— Presentation transcript:

1 Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study 
Ryutaro Kakinuma, MD, PhD, Masayuki Noguchi, MD, PhD, Kazuto Ashizawa, MD, PhD, Keiko Kuriyama, MD, PhD, Akiko Miyagi Maeshima, MD, PhD, Naoya Koizumi, MD, PhD, Tetsuro Kondo, MD, PhD, Haruhisa Matsuguma, MD, PhD, Norihisa Nitta, MD, PhD, Hironobu Ohmatsu, MD, PhD, Jiro Okami, MD, PhD, Hiroshi Suehisa, MD, PhD, Taiki Yamaji, MD, PhD, Ken Kodama, MD, PhD, Kiyoshi Mori, MD, PhD, Kouzo Yamada, MD, PhD, Yoshihiro Matsuno, MD, PhD, Sadayuki Murayama, MD, PhD, Kiyoshi Murata, MD, PhD  Journal of Thoracic Oncology  Volume 11, Issue 7, Pages (July 2016) DOI: /j.jtho Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2 Figure 1 Classification of subsolid nodules. (A) The first group of pure ground-glass nodules (GGNs), referred to here as pure GGNs, consisted of homogeneous opacities when viewed using the lung window. (B) A solid component in the mediastinal window was not observed. (C and D) The second group consisted of heterogeneous GGNs, or GGNs with a solid component (black arrow) in only the lung window but not in the mediastinal window. (E and F) The third group of part-solid nodules consisted of GGNs with a solid component both in the lung window (black arrow) and in the mediastinal window (white arrow). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3 Figure 2 Growth curves of subsolid nodules (SSNs). The red, green, and blue curves indicate the accumulated percentages of growth of pure ground-glass nodules (PGGNs), heterogeneous ground-glass nodules (HGGNs), and part-solid nodules, respectively. Each pair of colored lines on the right side of each graph shows the results of a log-rank test (i.e., the red and green lines indicate PGGNs versus HGGNs, whereas the red and blue lines indicate PGGNs versus part-solid nodules and the green and blue lines indicate HGGNs versus part-solid nodules, respectively). (A) Time until SSN growth of 2 mm or more according to SSN consistency. The 2-year and 5-year estimated probabilities of nodule growth were 2% and 14% for PGGNs, 12% and 24% for HGGNs, and 17% and 48% for part-solid nodules, respectively. Each pair of growth curves except for that for HGGNs and part-solid nodules showed a statistically significant difference after Bonferroni correction (*). (B) Time until the appearance of a solid component according to SSN consistency. The 2-year and 5-year estimated probabilities of the appearance of a solid component were 1% and 6% for PGGNs and 16% and 22% for HGGNs; the pair of growth curves showed a statistically significant difference. (C) Time until solid component growth of 2 mm or more according to SSN consistency. The 2-year and 5-year estimated probabilities of solid component growth were 0% and 2% for PGGNs, 0% and 5% for HGGNs, and 9% and 22% for part-solid nodules, respectively. Each pair of growth curves except for that for PGGNs and HGGNs showed a statistically significant difference after Bonferroni correction (*). Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

4 Figure 3 Time until pure ground-glass nodule (PGGN) growth according to the initial maximal diameter and sex. The red, green, blue, and orange curves indicate the accumulated percentages of growth of PGGNs with a maximal diameter larger than 10 mm in male patients, PGGNs with a maximal diameter larger than 10 mm in female patients, PGGNs with a maximal diameter of 10 mm or less in male patients, and PGGNs with a maximal diameter 10 mm or less in female patients, respectively. Each pair of colored lines on the right side of the graph shows the results of a log-rank test. Each pair except for that for PGGNs with a maximal diameter 10 mm or less in male patients and PGGNs with a maximal diameter 10 mm or less in female patients showed a statistically significant difference. However, all curves showed growth within 1 year. D, initial maximal diameter, N, number of patients. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

5 Figure 4 Follow-up periods until an increase in the diameter of the solid component in the part-solid nodules 3.3 mm or larger in maximal diameter. The mean period for the development of part-solid nodules with a solid component 3.3 mm or larger in maximal diameter was 4.2 ± 1.7 years for 20 part-solid nodules developed from pure ground-glass nodules (PGGNs), 4.2 ± 1.2 years for five part-solid nodules developed from heterogeneous ground-glass nodules (HGGNs), and 2.4 ± 1.3 years for 22 part-solid nodules with solid components 3 mm or smaller in maximal diameter at the first thin-section computed tomography scan, respectively. Journal of Thoracic Oncology  , DOI: ( /j.jtho ) Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

Download ppt "Natural History of Pulmonary Subsolid Nodules: A Prospective Multicenter Study  Ryutaro Kakinuma, MD, PhD, Masayuki Noguchi, MD, PhD, Kazuto Ashizawa,"

Similar presentations

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 

Kazuma Nagata, MD, Reiko Kaji, MD, Keisuke Tomii, MD 
Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for Growth  Miyako Hiramatsu, MD, Takuya Inagaki,

Pulmonary Ground-Glass Opacity (GGO) Lesions–Large Size and a History of Lung Cancer are Risk Factors for Growth  Miyako Hiramatsu, MD, Takuya Inagaki,
Combined small cell lung cancer originated from small pure ground-glass nodule— Long-term observation after computed tomography screening  Kentaro Miura,

Combined small cell lung cancer originated from small pure ground-glass nodule— Long-term observation after computed tomography screening  Kentaro Miura,
Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.

Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.
Informed consent obtained

Informed consent obtained
Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.

Long-Term Surveillance of Ground-Glass Nodules: Evidence from the MILD Trial  Silva Mario, MD, Sverzellati Nicola, MD, PhD, Manna Carmelinda, MD, Negrini.
Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.

Significance of the Number of Positive Lymph Nodes in Resected Non-small Cell Lung Cancer  Takayuki Fukui, MD, Shoichi Mori, MD, Kohei Yokoi, MD, Tetsuya.
Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.

Sequential Immunologic Reactions after Suspension of Nivolumab Treatment in Lung Adenocarcinoma Patient  Hiromichi Shirasu, MD, Akira Ono, MD, Toshiaki.
Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab  Tomoko Funazo,
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.

Successful Osimertinib Rechallenge in a Patient with T790M-Mutant Non–Small Cell Lung Cancer after Osimertinib-Induced Interstitial Lung Disease  Eisaku.
Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.

Acute and Progressive Tracheal Stenosis after Proton Beam Therapy with Concurrent Chemotherapy for Non–Small Cell Lung Cancer  Yoshitaka Zenke, MD, Shigeki.
Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.

Limited resection trial for pulmonary ground-glass opacity nodules: Fifty-case experience  Junji Yoshida, MD, Kanji Nagai, MD, Tomoyuki Yokose, MD, Mitsuyo.
Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A

Zachary S. Morris, MD, PhD, Donald M. Cannon, MD, Brett A
Epidemiology of Environmental Exposure and Malignant Mesothelioma

Epidemiology of Environmental Exposure and Malignant Mesothelioma
Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro.

Oncologic Outcomes of Segmentectomy Versus Lobectomy for Clinical T1a N0 M0 Non- Small Cell Lung Cancer  Ken Kodama, MD, Masahiko Higashiyama, MD, Jiro.
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P

Waleed Brinjikji, MD, Jennifer M. Boland Froemming, MD, William P
A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,

A Case of Concurrent De Novo C797S and L858R EGFR Mutation Detected in Stage IA Non–Small Cell Lung Cancer Patient  Jong Sik Lee, MD, Jae Young Hur, PhD,
Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Mariëlle I. Gallegos Ruiz, MSc, Hester van Cruijsen, MD, Egbert F

Similar presentations

Ads by Google